Effects of benfotiamine on the insulin resistance state, some pro- and anti-inflammatory factors content in patients with type 2 diabetes mellitus and cardiac autonomic neuropathy

Aim. The aim of the study was to analyze the effect of benfotiamine (BFT) on the insulin resistance state, the content of some pro- and anti-inflammatory factors in patients with type 2 diabetes mellitus (T2DM) and advanced stage of cardiac autonomic neuropathy (CAN).

Material and methods. 40 patients with T2DM and advanced stage of CAN, aged between 50-59 yrs with disease term 1-6 yrs and average glycated hemoglobin A1c (HbA1c) 7,16%±0,19% were examined. Patients were divided into 2 groups. The patients from first group received standard hypoglycemic treatment (n=19, control) for three mo. To patients from the second (n=21, treatment group) was prescribed 300 mg/q.d. of the BFT in addition for three mo. The levels of blood glucose, HbA1c, immunoreactive insulin (IRI), high sensitivity C-reactive protein (hs-CRP), leptin, tumor necrosis factor-alpha (TNF-alpha), interleukins (IL)-6, IL-8 and IL-10 were determined. The Homeostasis Model Assessment (HOMA) insulin resistance (IR) index (HOMA-IR) parameters, TNF-alpha/IL-10 ratio were calculated.

Results. Treatment with BFT led to significant decrease in the concentration of IRI [Δ=-12,74%±1,42% (p<0,05)]; hs-CRP [Δ=-13,62%±1,96% (p<0,05)], TNF-alpha [Δ=-10,24%±1,54% (p<0,05)] and IL-6 [Δ=-15,41%±2,03% (p<0,05)] compared to the control group. At the same time, prescription of BFT does not affect the concentration of glucose, leptin, IL-8, IL-10; HOMA-IR and TNF-alpha/IL-10 ratio parameters (p>0,05).

Conclusion. Obtained data may indicate a decrease in the activity of the proinflammatory link of the immune response and allow us to consider BFT as a promising pharmacological agent in the complex treatment of the advanced stage of CAN.

1. Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40: 136-54. doi: 10.2337/dc16-2042.

2. Serhiyenko V, Serhiyenko A. Cardiac autonomic neuropathy: risk factors, diagnosis and treatment. World J Diabetes. 2018;9: 1-24. doi: 10.4239/wjd.v9.il.1.

3. Lonsdale D, Marrs C. The autonomic nervous system and its functions. In: Lonsdale D, Marrs C, eds. Thiamine Deficiency Disease, Dysautonomia, And High Calorie Malnutrition. 1st ed. Oxford: Elsevier, 2017: 27-57). ISBN 9780128103883.

4. Boghdadi MA, Afify HE, Sabri N, et al. Comparative study of vitamin B complex combined with alpha lipoic acid versus vitamin B complex in treatment of diabetic polyneuropathy in type 2 diabetic patients. Clin Exp Pharmacol. 2017;7: 241. doi: 10.4172/2161-1459.1000241.

5. Oyenihi AB, Ayeleso AO, Mukwevho E, et al. Antioxidant strategies in the management of diabetic neuropathy. Biomed Res Int. 2015;2015: 515042. doi: 10.1155/2015/515042.

6. American Diabetes Association. Standards of medical care in diabetes-2017. Diabetes Care. 2017;40: 1-132. doi: 10.2337/dc17-S013.

7. Moss CJ, Mathews ST. Thiamin status and supplementation in the management of diabetes mellitus and its vascular comorbidities. Vitam Miner. 2013;2: 111. doi: 10.4172/vms.1000111.

8. Pácal L, Kuricová K, Kaňková K. Evidence for altered thiamine metabolism in diabetes: is there a potential to oppose gluco- and lipotoxicity by rational supplementation? World J Diabetes. 2014;5: 288-95. doi: 10.4239/wjd.v5.i3.288.

9. Luong KV, Nguyen LT. The impact of thiamine treatment in the diabetes mellitus. J Clin Med Res. 2012;4: 153-60. doi: 10.4021/jocmr890w.

10. Sandireddy R, Yerra VG, Areti A, et al. Neuroinflammation and oxidative stress in diabetic neuropathy: futuristic strategies based on these targets. Int J Endocrinol. 2014;2014: 674987. doi: 10.1155/2014/674987.

11. Serhiyenko V, Hotsko M, Snitynska O, et al. Benfotiamine and type 2 diabetes mellitus. MOJPH. 2018;7: 00200. doi: 10.15406/mojph.2018.07.00200.

12. Spallone V. Might genetics play a role in understanding and treating diabetic polyneuropathy? Diabetes Metab Res Rev. 2017;33: e2882. doi: 10.1002/dmrr.2882.

13. Mirza S, Hossain M, Mathews C, et al. Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans: a cross-sectional study. Cytokine. 2012;57: 136-42. doi: 10.1016/j.cyto.2011.09.029.

14. Valdes-Ramos R, Guadarrama-Lopez AL, Martinez-Carrillo BE, et al. Vitamins and type 2 diabetes mellitus. Endocr Metab Immune Disord Drug Targets. 2015;15: 54-63. doi: 10.2174/187153031466614111103217.